130 Billion to 1.5 Billion in 2 Years, PCL Expected to Reflect Losses
Will Olix Also Be Affected... Worst Case Scenario Includes Capital Erosion

[At a Crossroads] Olix Faces Loss Risk Due to Low-Price Sale of MCurex from PCL View original image

PCle, a KOSDAQ-listed company, has put Olix in a difficult position by transferring its stake in affiliate MQrex at a low price. Although PCle will incur a significant loss from this transaction, Olix, which holds a large amount of MQrex shares, may also face losses if it reflects this transaction price as the book value.


According to the Financial Supervisory Service's electronic disclosure system on the 8th, PCle disposed of 36.9% of its stake in MQrex for 1.484 billion KRW on the 31st of last month. The transferee was Yeom Juhwan, CEO of MQrex. CEO Yeom previously served as a research team leader at PCle's research institute.


PCle acquired 36.9% of MQrex shares for 13 billion KRW in December 2022. MQrex was established in January 2021 as a corporation with 51% investment from Olix. It was founded during the COVID-19 pandemic with the aim of developing mRNA vaccines and therapeutics.


As of the end of the third quarter last year, the book value of PCle’s 36.9% stake in MQrex was 13 billion KRW according to PCle’s quarterly report. Since this transaction occurred in the fourth quarter of last year, a book loss of approximately 11.5 billion KRW is expected to be recorded in the 2024 financial results.


In November 2022, PCle had valued MQrex at about 35 billion KRW using the discounted cash flow (DCF) method. This method calculated the corporate value by converting future revenues from license-outs (LO) and other sources into present value.


However, this time, the valuation was conducted applying the Inheritance and Gift Tax Act. MQrex’s value was calculated as a weighted average of net asset value and net income value. The net income value per share was 0 KRW, and the net asset value per share was applied as 3,426 KRW, resulting in a final per-share value of 2,749 KRW. Despite the nature of a new drug development company, which has no sales and thus cannot generate net income value, this method was applied.


Moreover, PCle and CEO Yeom Juhwan mutually agreed to transfer the shares at a 29% discounted price of 1,952 KRW per share. The entire value of MQrex was considered to be 4 billion KRW in this transaction.


The market suggests that this transaction could also affect Olix. As of the end of the third quarter last year, Olix held 25.97% of MQrex shares, with a book value of 7.7 billion KRW. Olix reflects the total value of MQrex as 29.8 billion KRW.


If Olix reflects the MQrex value of 4 billion KRW, as assessed in this transfer transaction by PCle, the value of Olix’s stake would drop to the 1 billion KRW range. This could result in an impairment loss of 6.7 billion KRW.


If such a loss occurs, Olix could fall into capital erosion. As of the end of the third quarter last year, Olix’s total equity on a separate basis was 16.6 billion KRW, with capital stock of 8.6 billion KRW. Additionally, Olix recorded a net loss of 28.7 billion KRW during the third quarter, averaging a loss of 9.5 billion KRW per quarter. If similar losses continue in the fourth quarter and the MQrex impairment loss is also reflected, most of Olix’s equity could disappear.


On the other hand, PCle has no concerns about capital erosion even after reflecting this loss. As of the end of the third quarter last year, PCle’s total equity was 51.7 billion KRW, with capital stock of 29.6 billion KRW. PCle’s cumulative net loss on a separate basis for the third quarter was 9 billion KRW.


Regarding this, an Olix official stated, “The finance team is discussing with the audit firm and MQrex,” adding, “To reduce losses in the fourth quarter of last year, cost control was strengthened, so losses will not be at the same level as previous quarters, and convertible bonds (CB) were also converted, so there is no concern about capital erosion.”



Meanwhile, on the 3rd, Olix filed a provisional injunction with the Seoul Southern District Court to inspect and copy PCle’s accounting books.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing